Create issue ticket

6,479 Possible Causes for Activating, Factor, Platelet

  • Bleeding Diathesis

    Serum plasminogen (40%, normal 72-128%) and alpha 2-antiplasmin (55%, normal 70-145%) activities were decreased.[] Additionally, FCA is able to identify discrete platelet activation defects.[] These discrepancies between Factor V activities and antigen concentration do not appear to be due to an unstable Factor V molecule or to the presence of a Factor V or Factor[]

  • Thrombotic Thrombocytopenic Purpura

    INTRODUCTION: Quantitation of ADAMTS13 activity, functional inhibitors, and autoantibodies is crucial in diagnosis and management of thrombotic thrombocytopenic purpura.[] BACKGROUND: Platelet microparticles (PMPs) have a procoagulant activity about 50-100 times greater than active platelets due to high expression of negatively charged phospholipids[] Most cases in adults are caused by acquired autoantibodies that inhibit ADAMTS13, a metalloprotease that cleaves von Willebrand factor within nascent platelet-rich thrombi[]

  • Acquired Von Willebrand Syndrome

    Abstract A case of acquired von Willebrand's syndrome (vWs) is described which appeared to be due to antibodies directed against factor VIII clotting activity (FVIIIC), factor[] Platelet dysfunction and acquired von Willebrand syndrome (AVWS) may contribute to bleeding tendencies.[] At diagnosis, VWF activity (VWF:Act), antigen (VWF:Ag), multimers, and factor VIII coagulant activity were virtually absent.[]

  • Acquired Thrombotic Thrombocytopenic Purpura

    Twenty plasma samples with non-concordant ADAMTS13 activity results, KEYWORDS: ADAMTS13 activity assay; TTP; autoantibodies; flow assay; von Willebrand factor[] Maximal increase of platelet adhesion was observed under 2,050 s(-1) .[] […] agglutination in patients with thrombotic thrombocytopenic purpura (TTP) appears to be associated with excessive release from endothelial cells of unusually large von Willebrand factor[]

  • Factor V Deficiency

    Recently, we have shown that three patients with undetectable plasma FV and mild bleeding symptoms had sufficient residual platelet FV to support thrombin generation in platelet-rich[] BACKGROUND AND OBJECTIVES: Factor V HR2 possesses decreased co-factor activity to activated protein C and an increased ratio of factor V1 to factor V2.[] activate factor X and prothrombin on the surface of activated platelets.[]

  • Von Willebrand Disease

    KEYWORDS: bleeding score; fibrinolysis; plasminogen activator inhibitor-1; von Willebrand disease[] A vaginal delivery was desired and plans were made for induction of labour at 38 weeks of gestation with platelet cover in view of the progressive fall of the platelet count[] […] with von Willebrand factor (VWF)/Factor VIII concentrate (Humate-P, CSL Behring) during the bridge to VAD replacement.[]

  • Coagulation Abnormalities

    The deficiencies may be the result of consumption of coagulation factors caused by ongoing low-level coagulation activation. possibly due to mononuclear cell activation.[] Platelet aggregation studies should be considered in patients with TSC.[] DVT is caused by an interaction between congenital coagulation abnormalities and acquired risk factors.[]

  • Atypical Hemolytic Uremic Syndrome

    […] as "cryptic activity of aHUS."[] […] of platelets with purified CFH.[] She showed only one cardiovascular risk factor, hypercholesterolaemia.[]

  • Disseminated Intravascular Coagulation

    Plasma ADAMTS-13 activity determined at diagnosis of DIC may help predict the risk of hemorrhagic events during and/or following DIC treatment with hematologic disorders.[] platelet aggregation in DIC.[] Within the JAAM DIC score, PT-INR 1.2 was the most accurate factor for T-DIC diagnosis; sensitivity 60.0%, specificity 100.0%, and accuracy 88.7%.[]

  • Osteoporosis

    Moreover, compounds 3 , 6 - 9 , and 11 significantly suppressed TRAP activities.[] Complete blood and platelet counts prior to zoledronic acid infusion were normal (138,000/µL), but had declined slightly from 185,000/µL 2 years ago.[] The aim of this study was to identify factors associated with osteoporosis treatment in postmenopausal women.A cross-sectional study was carried out from March to August 2013[]